Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | -0.64 | -0.24 | 0.03 |
| FCF Yield | 4.92% | 1.52% | -10.49% | 1.02% |
| EV / EBITDA | 31.88 | 14.46 | 8.37 | -5.35 |
| Quality | ||||
| ROIC | 0.78% | 0.67% | 7.90% | 41.67% |
| Gross Margin | 48.47% | 46.83% | 52.22% | 54.04% |
| Cash Conversion Ratio | 2.46 | 1.25 | -2.72 | -0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.88% | 1.44% | -4.51% | -6.42% |
| Free Cash Flow Growth | 462.25% | 108.14% | -696.44% | -88.23% |
| Safety | ||||
| Net Debt / EBITDA | -9.45 | -2.90 | -1.51 | 1.46 |
| Interest Coverage | 0.00 | 14.14 | 111.53 | 516.83 |
| Efficiency | ||||
| Inventory Turnover | 1.58 | 1.34 | 1.27 | 1.40 |
| Cash Conversion Cycle | 283.26 | 343.57 | 383.69 | 340.45 |